Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Centre for Addiction and Mental Health, Toronto, Ontario, Canada
  2. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
  3. University Health Network, Toronto, Ontario, Canada
  4. Centre for Addiction and Mental Health, Toronto, Ontario, Canada
  5. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
  6. Department of Psychiatry, Credit Valley Hospital, Mississauga, Ontario, Canada
  7. Chatham-Kent Clinical Trials Research Centre, Chatham, Ontario, Canada
  8. Centre for Addiction and Mental Health, Toronto, Ontario, Canada
  9. Centre for Addiction and Mental Health, Toronto, Ontario, Canada
  10. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
  11. Corresponding author: Arun V. Ravindran, MD, 100 Stokes St, Toronto, ON M6J 1H4 Canada ([email protected]).
  1. Mathers CBT, Ma Fat D. The Global Burden of Disease: 2004 Update. WHO website. https://apps.who.int/iris/bitstream/handle/10665/43942/9789241563710_eng.pdf. 2008.
  2. Whiteford HAP, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1575–1586. PubMed CrossRef
  3. Remes O, Brayne C, van der Linde R, et al. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain Behav. 2016;6(7):e00497. PubMed CrossRef
  4. Kessler RC, Sampson NA, Berglund P, et al. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiol Psychiatr Sci. 2015;24(3):210–226. PubMed CrossRef
  5. Kessler RC, Berglund P, Demler O, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–3105. PubMed CrossRef
  6. Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9(1):90. PubMed CrossRef
  7. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–627. PubMed CrossRef
  8. Gaspersz R, Nawijn L, Lamers F, et al. Patients with anxious depression: overview of prevalence, pathophysiology and impact on course and treatment outcome. Curr Opin Psychiatry. 2018;31(1):17–25. PubMed CrossRef
  9. May AM, Klonsky ED, Klein DN. Predicting future suicide attempts among depressed suicide ideators: a 10-year longitudinal study. J Psychiatr Res. 2012;46(7):946–952. PubMed CrossRef
  10. Sareen J, Cox BJ, Afifi TO, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry. 2005;62(11):1249–1257. PubMed CrossRef
  11. Belzer K, Schneier FR. Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment. J Psychiatr Pract. 2004;10(5):296–306. PubMed CrossRef
  12. Kennedy SH, Lam RW, McIntyre RS, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry. 2016;61(9):540–560. PubMed CrossRef
  13. Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. Focus Am Psychiatr Publ. 2016;14(2):244–265. PubMed CrossRef
  14. Vieta E, Earley WR, Burgess MV, et al. Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder. Int Clin Psychopharmacol. 2019;34(2):76–83. PubMed CrossRef
  15. Yoon S, Jeon SW, Ko Y-H, et al. Adjunctive brexpiprazole as a novel effective strategy for treating major depressive disorder: a systematic review and meta-analysis. J Clin Psychopharmacol. 2017;37(1):46–53. PubMed CrossRef
  16. Albert U, Carmassi C, Cosci F, et al. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. Int Clin Psychopharmacol. 2016;31(5):249–258. PubMed CrossRef
  17. Pignon B, Tezenas du Montcel C, Carton L, et al. The place of antipsychotics in the therapy of anxiety disorders and obsessive-compulsive disorders. Curr Psychiatry Rep. 2017;19(12):103. PubMed CrossRef
  18. de Miranda AS, Ferreira RN, Teixeira AL, et al. Mood Stabilizers: Quetiapine. NeuroPsychopharmacotherapy; 2020:1–23.
  19. Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology. 2008;33(10):2303–2312. PubMed CrossRef
  20. Duncan D, Cooke L, Symonds C, et al. Quetiapine use in adults in the community: a population-based study in Alberta, Canada. BMJ Open. 2016;6(3):e010861. PubMed CrossRef
  21. Ketter TA, Miller S, Dell’Osso B, et al. Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium. J Affect Disord. 2016;191:256–273. PubMed CrossRef
  22. Ignácio ZM, Calixto AV, da Silva RH, et al. The use of quetiapine in the treatment of major depressive disorder: evidence from clinical and experimental studies. Neurosci Biobehav Rev. 2018;86:36–50. PubMed CrossRef
  23. Maneeton N, Maneeton B, Woottiluk P, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2016;10:259–276. PubMed CrossRef
  24. Stein DJ, Bandelow B, Merideth C, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol. 2011;26(8):614–628. PubMed CrossRef
  25. Endicott J, Svedsäter H, Locklear JC. Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder. Neuropsychiatr Dis Treat. 2012;8:301–311. PubMed CrossRef
  26. Thase ME, Demyttenaere K, Earley WR, et al. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety. 2012;29(7):574–586. PubMed CrossRef
  27. Bandelow B, Bauer M, Vieta E, et al. Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. World J Biol Psychiatry. 2014;15(2):155–166. PubMed CrossRef
  28. McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007;24(7):487–494. PubMed CrossRef
  29. Li X, Xing B, Yu E, et al. The combined treatment of venlafaxine and quetiapine for treatment-resistant depression: a clinical study. J Neuropsychiatry Clin Neurosci. 2013;25(2):157–160. PubMed CrossRef
  30. Li R, Wu R, Chen J, et al. A randomized, placebo-controlled pilot study of quetiapine-XR monotherapy or adjunctive therapy to antidepressant in acute major depressive disorder with current generalized anxiety disorder. Psychopharmacol Bull. 2016;46(1):8–23. PubMed
  31. Chen Y-C, Chen C-K, Wang L-J. Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study. BMC Psychiatry. 2012;12(1):162. PubMed CrossRef
  32. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders: Patient Edition. Biometrics Research Department, Columbia University: New York, NY; 2005.
  33. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62. PubMed CrossRef
  34. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55. PubMed CrossRef
  35. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service; 1976.
  36. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389. PubMed CrossRef
  37. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561–571. PubMed CrossRef
  38. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321–326. PubMed
  39. Meyer TJ, Miller ML, Metzger RL, et al. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487–495. PubMed CrossRef
  40. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141–173. PubMed CrossRef
  41. Shear MK, Brown TA, Barlow DH, et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997;154(11):1571–1575. PubMed CrossRef
  42. McIntyre RS, Muzina DJ, Adams A, et al. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother. 2009;10(18):3061–3075. PubMed CrossRef
  43. Stein MB, Fuetsch M, Müller N, et al. Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults. Arch Gen Psychiatry. 2001;58(3):251–256. PubMed CrossRef
  44. Bandelow B, Reitt M, Röver C, et al. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30(4):183–192. PubMed CrossRef
  45. de Graaf R, Bijl RV, Ten Have M, et al. Pathways to comorbidity: the transition of pure mood, anxiety and substance use disorders into comorbid conditions in a longitudinal population-based study. J Affect Disord. 2004;82(3):461–467. PubMed CrossRef
  46. Khan A, Detke M, Khan SR, et al. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis. 2003;191(4):211–218. PubMed CrossRef
  47. Maslej MM, Furukawa TA, Cipriani A, et al. Individual differences in response to antidepressants: a meta-analysis of placebo-controlled randomized clinical trials. JAMA Psychiatry. 2020;77(6):607–617. Retracted in: JAMA Psychiatry. 2020;77(8):786.  PubMed CrossRef
  48. McElroy SL, Weisler RH, Chang W, et al; EMBOLDEN II (Trial D1447C00134) Investigators. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163–174. PubMed CrossRef
  49. Young AH, McElroy SL, Bauer M, et al; EMBOLDEN I (Trial 001) Investigators. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010;71(2):150–162. PubMed CrossRef
  50. Thase ME, Macfadden W, Weisler RH, et al; BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600–609. PubMed CrossRef
  51. Hirschfeld RM, Weisler RH, Raines SR, et al; BOLDER Study Group. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67(3):355–362. PubMed CrossRef
  52. Thase ME. Quetiapine monotherapy for bipolar depression. Neuropsychiatr Dis Treat. 2008;4(1):11–21. PubMed CrossRef
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe now